📣 VC round data is live. Check it out!
- Public Comps
- Oncology Institute
Oncology Institute Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oncology Institute and similar public comparables like Cross Country Healthcare, LNA Sante, Propel Funeral Partners, Oceania Healthcare and more.
Oncology Institute Overview
About Oncology Institute
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
Founded
2007
HQ

Employees
825
Website
Sectors
Financials (LTM)
EV
$534M
Valuation Multiples
Start free trialOncology Institute Financials
Oncology Institute reported last 12-month revenue of $564M and negative EBITDA of ($6M).
In the same LTM period, Oncology Institute generated $87M in gross profit, ($6M) in EBITDA losses, and had net loss of ($37M).
Revenue (LTM)
Oncology Institute P&L
In the most recent fiscal year, Oncology Institute reported revenue of $503M and EBITDA of ($12M).
Oncology Institute is unprofitable as of last fiscal year, with gross margin of 15%, EBITDA margin of (2%), and net margin of (10%).
Financial data powered by Morningstar, Inc.
Oncology Institute Stock Performance
Oncology Institute has current market cap of $459M, and enterprise value of $534M.
Market Cap Evolution
Oncology Institute's stock price is $4.59.
Oncology Institute share price increased by 18.7% in the last 30 days, and by 44.0% in the last year.
Oncology Institute has an EPS (earnings per share) of $-0.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $534M | $459M | 0.0% | 18.7% | 59.8% | 44.0% | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOncology Institute Valuation Multiples
Oncology Institute trades at 0.9x EV/Revenue multiple, and (94.3x) EV/EBITDA.
EV / Revenue (LTM)
Oncology Institute Financial Valuation Multiples
As of May 26, 2026, Oncology Institute has market cap of $459M and EV of $534M.
Oncology Institute has a P/E ratio of (12.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oncology Institute Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Oncology Institute Margins & Growth Rates
Oncology Institute grew revenue by 30% but EBITDA decreased by 136% in the last fiscal year.
In the most recent fiscal year, Oncology Institute reported gross margin of 15%, EBITDA margin of (2%), and net margin of (10%).
Oncology Institute Margins
Oncology Institute Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Oncology Institute Operational KPIs
Oncology Institute's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
Oncology Institute's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncology Institute's Rule of X is 76% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Oncology Institute Competitors
Oncology Institute competitors include Cross Country Healthcare, LNA Sante, Propel Funeral Partners, Oceania Healthcare, Enhabit, Eureka Group Holdings, Joint, Radius Residential, DocGo and InnovAge.
Most Oncology Institute public comparables operate across Long-Term Care.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.3x | 0.3x | 11.2x | 11.4x | |||
| 1.2x | 1.2x | 7.4x | 8.0x | |||
| 3.0x | 2.9x | 12.4x | 11.3x | |||
| 4.4x | 3.3x | 16.8x | 16.6x | |||
| — | 1.1x | — | 10.6x | |||
| 7.9x | 7.2x | 10.8x | 18.0x | |||
| 2.0x | 1.9x | 8.4x | 8.7x | |||
| 1.8x | 1.5x | 10.4x | 8.7x | |||
This data is available for Pro users. Sign up to see all Oncology Institute competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oncology Institute
| When was Oncology Institute founded? | Oncology Institute was founded in 2007. |
| Where is Oncology Institute headquartered? | Oncology Institute is headquartered in United States. |
| How many employees does Oncology Institute have? | As of today, Oncology Institute has over 825 employees. |
| Who is the CEO of Oncology Institute? | Oncology Institute's CEO is Daniel Virnich. |
| Is Oncology Institute publicly listed? | Yes, Oncology Institute is a public company listed on Nasdaq. |
| What is the stock symbol of Oncology Institute? | Oncology Institute trades under TOI ticker. |
| When did Oncology Institute go public? | Oncology Institute went public in 2021. |
| Who are competitors of Oncology Institute? | Oncology Institute main competitors include Cross Country Healthcare, LNA Sante, Propel Funeral Partners, Oceania Healthcare, Enhabit, Eureka Group Holdings, Joint, Radius Residential, DocGo, InnovAge. |
| What is the current market cap of Oncology Institute? | Oncology Institute's current market cap is $459M. |
| What is the current revenue of Oncology Institute? | Oncology Institute's last 12 months revenue is $564M. |
| What is the current revenue growth of Oncology Institute? | Oncology Institute revenue growth (NTM/LTM) is 28%. |
| What is the current EV/Revenue multiple of Oncology Institute? | Current revenue multiple of Oncology Institute is 0.9x. |
| Is Oncology Institute profitable? | No, Oncology Institute is not profitable. |
| What is the current EBITDA of Oncology Institute? | Oncology Institute has negative EBITDA and is not profitable. |
| What is Oncology Institute's EBITDA margin? | Oncology Institute's last 12 months EBITDA margin is (1%). |
| What is the current EV/EBITDA multiple of Oncology Institute? | Current EBITDA multiple of Oncology Institute is (94.3x). |
| What is the current FCF of Oncology Institute? | Oncology Institute's last 12 months FCF is ($24M). |
| What is Oncology Institute's FCF margin? | Oncology Institute's last 12 months FCF margin is (4%). |
| What is the current EV/FCF multiple of Oncology Institute? | Current FCF multiple of Oncology Institute is (22.4x). |
| How many companies Oncology Institute has acquired to date? | Oncology Institute hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Oncology Institute has invested to date? | Oncology Institute hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Oncology Institute
Lists including Oncology Institute
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.